Lilly tames Fauna to go on the prowl for obesity targets in $494M deal

Last month, Eli Lilly executives said that when it comes to expanding its obesity pipeline, the Zepbound-maker is in “all-of-the-above mode.” Judging by its partnership with animal genomics-focused Fauna Bio, the Big Pharma really meant it.